These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 15135652

  • 1. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells.
    Carrion C, de Madariaga MA, Domingo JC.
    Life Sci; 2004 Jun 04; 75(3):313-28. PubMed ID: 15135652
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE, Pilarski LM, Allen TM.
    Cancer Res; 1998 Aug 01; 58(15):3320-30. PubMed ID: 9699662
    [Abstract] [Full Text] [Related]

  • 3. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H.
    Int J Pharm; 2007 Feb 01; 329(1-2):94-102. PubMed ID: 16997518
    [Abstract] [Full Text] [Related]

  • 4. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
    Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, van Blitterswijk WJ.
    J Pharmacol Exp Ther; 2005 Nov 01; 315(2):704-10. PubMed ID: 16040815
    [Abstract] [Full Text] [Related]

  • 5. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW, Allen TM.
    J Control Release; 2008 Feb 18; 126(1):50-8. PubMed ID: 18068849
    [Abstract] [Full Text] [Related]

  • 6. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J, Lee A, Lu Y, Lee RJ.
    Int J Pharm; 2007 Jun 07; 337(1-2):329-35. PubMed ID: 17275230
    [Abstract] [Full Text] [Related]

  • 7. Disaccharide-modified liposomes and their in vitro intracellular uptake.
    Song CK, Jung SH, Kim DD, Jeong KS, Shin BC, Seong H.
    Int J Pharm; 2009 Oct 01; 380(1-2):161-9. PubMed ID: 19635539
    [Abstract] [Full Text] [Related]

  • 8. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee RJ.
    J Pharm Pharm Sci; 2007 Oct 01; 10(3):350-7. PubMed ID: 17727798
    [Abstract] [Full Text] [Related]

  • 9. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.
    Sawant RM, Cohen MB, Torchilin VP, Rokhlin OW.
    J Drug Target; 2008 Aug 01; 16(7):601-4. PubMed ID: 18686131
    [Abstract] [Full Text] [Related]

  • 10. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
    He X, Na MH, Kim JS, Lee GY, Park JY, Hoffman AS, Nam JO, Han SE, Sim GY, Oh YK, Kim IS, Lee BH.
    Mol Pharm; 2011 Apr 04; 8(2):430-8. PubMed ID: 21222482
    [Abstract] [Full Text] [Related]

  • 11. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM, Mumbengegwi DR, Charrois GJ.
    Clin Cancer Res; 2005 May 01; 11(9):3567-73. PubMed ID: 15867261
    [Abstract] [Full Text] [Related]

  • 12. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization.
    Tinkov S, Winter G, Coester C, Bekeredjian R.
    J Control Release; 2010 Apr 02; 143(1):143-50. PubMed ID: 20060861
    [Abstract] [Full Text] [Related]

  • 13. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
    Pastorino F, Mumbengegwi DR, Ribatti D, Ponzoni M, Allen TM.
    J Control Release; 2008 Feb 18; 126(1):85-94. PubMed ID: 18166243
    [Abstract] [Full Text] [Related]

  • 14. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC, Liu XY, Lü WL, Lee HS, Goh BC, Zhang Q.
    Yao Xue Xue Bao; 2005 May 18; 40(5):475-80. PubMed ID: 16220797
    [Abstract] [Full Text] [Related]

  • 15. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X, Ding L, Xu Y, Wang Y, Ping Q.
    Int J Pharm; 2009 May 21; 373(1-2):116-23. PubMed ID: 19429296
    [Abstract] [Full Text] [Related]

  • 16. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
    Simard P, Leroux JC.
    Int J Pharm; 2009 Nov 03; 381(2):86-96. PubMed ID: 19446624
    [Abstract] [Full Text] [Related]

  • 17. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
    Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, Löbenberg R, Roa WH.
    Int J Pharm; 2006 Aug 17; 319(1-2):155-61. PubMed ID: 16713150
    [Abstract] [Full Text] [Related]

  • 18. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
    Shao K, Hou Q, Duan W, Go ML, Wong KP, Li QT.
    J Control Release; 2006 Oct 10; 115(2):150-7. PubMed ID: 16963144
    [Abstract] [Full Text] [Related]

  • 19. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells.
    Lu Y, Wu J, Wu J, Gonit M, Yang X, Lee A, Xiang G, Li H, Liu S, Marcucci G, Ratnam M, Lee RJ.
    Mol Pharm; 2007 Oct 10; 4(5):707-12. PubMed ID: 17708654
    [Abstract] [Full Text] [Related]

  • 20. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
    Gaber MH.
    J Biochem Mol Biol Biophys; 2002 Oct 10; 6(5):309-14. PubMed ID: 12385965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.